Posts filtered by tags: Pacific Biosciences[x]


Scientists Can Now Assemble Entire Genomes On Their Personal Computers In Minutes

Researchers have developed a technique for reconstructing whole genomes, including the human genome, on a personal computer. "This technique is about a hundred times faster than current state-of-the-art approaches and uses one-fifth the resources," reports Phys.Org. From the report: The study, published September 14 in the journal Cell Systems, allows for a more compact representation of genome data inspired by the way in which words, rather than letters, offer condensed building blocks for lang...
Tags: Tech, Hifi, Peregrine, Pacific Biosciences, Cell Systems

United States: Federal Circuit Affirms Invalidity Of Nanopore Sequencing Patents For Failing To Enable, And Affirms Denial Of New Trial On The Basis Of Defendant's Allegedly Prejudicial Remarks Regarding The COVID-19 Crisis - Haug Partners

On May 11, 2021, the Federal Circuit affirmed the District Court of Delaware's judgment that patents belonging to Pacific Biosciences of California ("PacBio") were invalid for lack of enablement under 35 U.S.C. § 112.
Tags: News, California, United States, Federal Circuit, Pacific Biosciences, District Court of Delaware

Ginkgo’s Insanely Great $15B Deal, The Who & How Behind Biggest Sector Deal Ever

In Massachusetts, Ginkgo Bioworks and Soaring Eagle Acquisition Corp. have agreed to a business combination that will result in Ginkgo becoming a publicly-listed company. The transaction is expected to close in the third quarter of 2021. The $15B valuation and $2.5B to Ginkgo in proceeds The transaction implies a pre-money equity valuation for Ginkgo of $15.0 billion, and is expected to provide up to $2.5 billion of gross cash proceeds. Gross proceeds include Soaring Eagle’s $1.725 billion o...
Tags: Unilever, Top Stories, Jason, Palantir, Delaware, Illumina, Bayer, Board, Kelly, Thermo Fisher Scientific, Jason Kelly, Arie, Pacific Biosciences, Shetty, Soaring Eagle, Kite Pharma

Invitae surges after report says Softbank will lead a $1.2 billion investment in the genetic-testing company

Courtesy of Invitae The genetic testing company Invitae is set to receive a $1.2 billion investment led by Softbank. Invitae also announced it will acquire a genomics company, Genosity, in a $200 million deal. The firm turned in revenues of $280 million and a net loss of $602 million for the full year 2020. Sign up here for our daily newsletter, 10 Things Before the Opening Bell. Invitae stock surged as much as 7% on Monday after a report out of the Wall Street Journal said Softbank plans...
Tags: Softbank, San Francisco, Trends, SEC, Wood, Wall Street Journal, Cnbc, Pacific Biosciences, InVitae, Cathie Wood, ARK Invest, Will Daniel, Softbank Invitae, Genosity, Things Before the Opening Bell Invitae, February Invitae

Dow closes at record high after Powell backs continued low interest rates

Federal Reserve Board Chairman Jerome Powell testifies during a hearing on "The Semiannual Monetary Policy Report to the Congress," in front of the Senate Banking, Housing and Urban Affairs Committee in the Dirksen Senate Office Building on February 12, 2020 in Washington, DC. Sarah Silbiger/Getty Images The Dow closed at a record high on Wednesday after Federal Reserve Chairman Jerome Powell expressed his support for continued low interest rates.In a speech to the Economic Club of New York...
Tags: Lyft, Elon Musk, New York, Congress, Washington, Softbank, US, NFL, Colin Kaepernick, Interest Rates, Trends, Markets, Tesla, Credit Suisse, West Texas Intermediate, Federal Reserve

Pacific Biosciences spikes 29% after announcing a $900 million investment from SoftBank

Reuters/Issei Kato Pacific Biosciences stock skyrocketed on Wednesday amid a reported $900 million investment from SoftBank. SoftBank's SB NorthStar unit will buy $900 million of notes with an initial conversion price of $43.50 per share. The SB NorthStar unit reported losses of $1.6 billion in SoftBank's most recent earnings release.  Sign up here for our daily newsletter, 10 Things Before the Opening Bell. Pacific Biosciences spiked as much as 29% on Wednesday before paring gains after ...
Tags: UK, Softbank, Trends, United States, Credit Suisse, Illumina, Roche, Northstar, PacBio, Pacific Biosciences, Christian Henry, Kahoot, Akshay Naheta, SoftBank SoftBank, Invitae Corp, SB Northstar

Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More

Gilead Sciences CEO Daniel O’Day has spoken openly about acquisitions as a way to build up the company’s drug pipeline. This week, it made its biggest buy yet.The $21 billion Immunomedics acquisition brings to Gilead a cancer drug that many analysts project will become a blockbuster seller. Some of those analysts think Gilead might have overpaid but the company says there were competing offers. The drug, sacitizumab govitecan (Trodelvy), is what’s called an antibody drug conjugate (ADC). This d...
Tags: Deals, Startups, Cancer, Hiv, Trends, Merck, Alzheimer's Disease, Astrazeneca, Fda, National, Novartis, Pfizer, Abbvie, Biotech, Medical Device, Microbiome

Bio Roundup: Seres Soars, MesoBlast Vote, Duchenne Decision & More

The road of drug development is rife with detours and disappointments but Seres Therapeutics showed this week that course corrections can work. Four years after its microbiome therapy failed in a mid-stage study, the company reported early positive data from a pivotal test of its treatment for a type of gut infection.The results are vindication for Cambridge, MA-based Seres (NASDAQ: MCRB). They’re also validation for the emerging microbiome medicines field, which has added many companies since ...
Tags: Deals, Startups, Trends, Investing, Inflammatory Bowel Disease, Ulcerative Colitis, Cambridge, Fda, National, Biotech, Menopause, Microbiome, Crispr, Galapagos, Life Sciences, Bayer

Bio Roundup: A Royal IPO, Akili Arrives, Orca Bio Surfaces & More

The biggest life sciences deal this week involves a company that doesn’t discover or develop drugs, or even sell them. Yet its mark is found on pharmaceutical products spanning the entire sector.Royalty Pharma (NASDAQ: RPRX) acquires the royalty rights for drugs. Most of those royalties are for products that are already approved, but the company has also been striking deals for compounds still in development. The biotechs forking over royalty rights get cash right away to continue the expensive...
Tags: Deals, Startups, Ipo, Trends, Neuroscience, Investing, Merck, Inflammatory Bowel Disease, National, GlaxoSmithKline, Allergan, Abbvie, Oxford University, Biotech, Vaccines, Liver disease

Bio Roundup: FDA Approvals, Intrexon’s Shift, Melinta Bankruptcy & More

In the week leading up to Christmas, six drugs won FDA approvals. The decisions covered insomnia, migraine, and several different forms of cancer.The FDA’s final tally for the year totaled 48 new drug approvals. If you’re keeping score, that compares with 59 approvals in 2018 and 46 in 2017. Most of the nods went to small molecule drugs and cancer drugs continued to represent a significant chunk of the new approved medicines. For what it’s worth, the FDA didn’t say how many drugs it rejected in...
Tags: Deals, Startups, Breast Cancer, Cancer, Trends, Investing, Merck, Anemia, Schizophrenia, Astrazeneca, Fda, National, Pfizer, Allergan, Biotech, Pancreatic Cancer

Bio Roundup: Amarin’s Approval, FTC v. Illumina, a $120M Deal & More

As national politics dominates the news in the final days of the decade, we at Xconomy are wrapping up the year with some big moves by the FDA, including an approval of the first drug OK’d reduce heart risk in patients with high triglycerides who are already taking statins.Holidays don’t provide immunity to bad news, however, and some companies, like Gilead Sciences (NASDAQ: GILD) and its investigational NASH drugs, didn’t get the clinical trial results they hoped for. The Federal Trade Commiss...
Tags: Deals, Startups, Trends, Venture Capital, Fda, National, Biotech, Federal Trade Commission, Illumina, Ftc, Life Sciences, Clinical Trials, Roche, Gilead Sciences, Medtronic, Nash

Improved mosquito reference genome assembly produced using long-read sequencing

A new comprehensive map of mosquito DNA has been assembled using long-read sequencing technology from California-based Pacific Biosciences. The improved reference genome assembly, published in Nature, could help scientists combat the pest and infectious diseases it spreads, including Zika, dengue, chikungunya, and yellow fever.
Tags: Science, California, Zika, Pacific Biosciences

Illumina signs agreement to acquire Pacific Biosciences

Illumina, Inc. and Pacific Biosciences today announced they have signed an agreement for Illumina to acquire Pacific Biosciences at a price of $8.00 per Pacific Biosciences share in an all-cash transaction.
Tags: Health, Illumina, Illumina Inc, Pacific Biosciences

Illumina Set to Acquire “Long-Read” DNA Sequencer PacBio for $1.2B

DNA sequencing giant Illumina is shoring up its position in genetic research through a cash deal to acquire Pacific Biosciences for approximately $1.2 billion.Under the agreement, Illumina (NASDAQ: ILMN) will pay $8 per Pacific Biosciences (NASDAQ: PACB) share, a 79 percent premium to the Wednesday closing stock price of the Menlo Park, CA, company.The company’s shares haven’t traded above $8 since November 2016. PacBio went public eight years ago at $16 per share.Though both Illumina and PacBi...
Tags: Deals, Trends, San Diego, Biotech, Illumina, Life Sciences, Gene Sequencing, Roche, PacBio, Pacific Biosciences, Jay Flatley, Francis deSouza, Diagnostics, National blog main, National top stories, San Francisco blog main

DNA sequencing giant Illumina just bought rival Pac Bio for $1.2 billion — here's why

Illumina just paid $1.2 billion for Pacific Biosciences, to help it retain its dominant position in the DNA sequencing space, biotech experts say. Illumina, which is valued at more than $45 billion, makes the machines that companies from 23andMe to Ancestry rely on for their sequencing. Illumina ILMN , the company that makes the machines that sequence the vast majority of human genomes, is buying a smaller competitor called Pacific Biosciences PACB for $1.2 billion.
Tags: Science, Illumina, Illumina ILMN, Pacific Biosciences, Pac Bio, Pacific Biosciences PACB

Pacific Biosciences surges on $1.2 billion takeover offer from DNA sequencing company Illumina (ILMN, PACB)

DNA sequencing company Illumina announced in a press release that it was acquiring Pacific Biosciences for approximately $1.2 billion. Illumina expects to close the transaction in mid-2019. Pacific Biosciences is a company that also specializes in gene sequencing.
Tags: Science, Illumina, Pacific Biosciences, PACB

Pacific Biosciences of California Revenue Up Thanks to More System Installs

Shipments delayed in the first quarter were installed in the second quarter, boosting the gene-sequencing company's revenue.
Tags: California, Finance, Article, FBN, Pacific Biosciences, Motley Fool, Fbn/markets, Fox-business/markets, 73a1f023-c105-5fe2-aa13-43e447ea0f5a

With New Test, Schadt’s Sema4 Aims to Broaden Scope of Newborn Screening

Sema4, the company that computational geneticist Eric Schadt spun out of the Icahn School of Medicine at Mount Sinai last year, is making a new bet this morning. The New York and Connecticut startup is launching a diagnostic, Sema4 Natalis, meant to go well beyond the typical tests hospitals run on newborn babies to check for serious diseases. Newborn screening exams in hospitals—blood tests given before a baby is discharged—are done to check for serious diseases like cystic fibrosis or s...
Tags: Deals, Startups, New York, Trends, Merck, Connecticut, Life Sciences, Mount Sinai, Department of Health and Human Services, Icahn School of Medicine, PerkinElmer, Pacific Biosciences, Mount Sinai Health System, Diagnostics, National blog main, New York blog main

Northeastern biophysics study makes exciting advancements for the future of DNA sequencing

A Northeastern research team has developed new technology that optimizes DNA sequencing using nanophysics and electric currents. In a paper published in Nature Nanotechnology, Northeastern Professor of Biological Physics Meni Wanunu, in partnership with Pacific Biosciences, a biotechnology company with a focus on DNA sequencing, developed a method for loading DNA into sequencing wells with orders of magnitude higher efficiencies.
Tags: Science, Pacific Biosciences

What's Behind Pacific Biosciences of California's Stock Rally Today?

Shares of Pacific Biosciences of California (NASDAQ: PACB) are on the rise again. This is the third trading session in a row that the stock has marched upwards since announcing record revenues and a big order for its next-generation genomic sequencers last week. The stock has tacked on a 11.7% gain as of 2:45 p.m. EDT on Monday.The stock has risen about 40% since Aug. 2. After the bell that afternoon, Pacific Biosciences announced a new agreement with genomic services giant Novogene. The latte...
Tags: California, Finance, Health Care, Pacific Biosciences, 10% Promise, Cory Renauer, PACB, RHHBY, 394c373c-7ba2-11e7-a249-0050569d4be0, Stock Rally Today

Here's Why Pacific Biosciences of California Is Surging Today

Shares of Pacific Biosciences of California  (NASDAQ: PACB) , a purveyor of high-accuracy genomic sequencing kits, is marching higher after reporting second-quarter earnings and a big order from a leading genetic-services provider. The news lifted the stock about 13.7% higher as of 3:42 p.m. EDT on Thursday.Stripping away significant contractual revenue recorded last year, second-quarter product and service sales rose 17% higher than the same period last year, to $20.1 million. Perhaps more impo...
Tags: California, Finance, Health Care, Pacific Biosciences, 10% Promise, Cory Renauer, PACB, E83d5a8c-787d-11e7-8f36-0050569d32b9

Pacific Biosciences of California Struggles in the Second Quarter With Lower Sales

Pacific Biosciences of California (NASDAQ: PACB) didn't fare so well the last time it provided a quarterly update. After the genetic-sequencing company reported its first-quarter results in late April, its bigger-than-expected net loss rattled investors. The company announced its second-quarter results after the market closed on Wednesday, and the news wasn't any better than earlier this year. Here are the highlights. Image source: Getty Images.Continue reading [Author: [email protected] (...
Tags: California, Finance, Health Care, Pacific Biosciences, ILMN, Keith Speights, PACB, 7d3c777e-77bd-11e7-8ab8-0050569d4be0, California Struggles

Sema4, Eric Schadt’s Genomics Startup, Spins Out of Sinai to Raise Cash

[Updated, 3:21 p.m. ET, see below] Eric Schadt has been incubating a genomic data project within the Icahn School of Medicine at Mount Sinai for more than five years. Today, the product of that work, a 300-plus employee startup called Sema4, has formally left the nest. Sema4 today spun out of Mount Sinai as a for-profit company and will be led by Schadt, an ex-Merck (NYSE: MRK) and Pacific Biosciences (NASDAQ: PACB) executive and the founding director of the Icahn Institute for Genomics a...
Tags: Startups, New York, Trends, Merck, Data, Genomics, Life Sciences, Mount Sinai, Icahn School of Medicine, Pacific Biosciences, Icahn Institute for Genomics, Multiscale Biology, National blog main, New York blog main, New York top stories, National top stories

Menlo Park Labs lands new biotech tenant after 'massive' building revamp

Pacific Biosciences of California has signed a 10-year lease at a 180,000-square-foot newly revamped building in Menlo Park Labs, an office and R&D park geared toward life science and biotech companies. The building at 1305 O’Brien Drive was recently transformed by developer Tarlton Properties Inc. from an Office Max distribution facility into the new corporate headquarters for Pacific Biosciences, also known as PacBio. The biotechnology company is known for both developing and manufacturing sy...
Tags: California, Pacific Biosciences, Office Max, Menlo Park Labs, O'Brien Drive, Tarlton Properties Inc

This Is the Big Reason Behind Pacific Biosciences of California, Inc.'s 24% Tumble in April

Shares of Pacific Biosciences of California (NASDAQ: PACB) , a developer and manufacturer of genetic sequencing machines, tumbled 24% in April, according to data from S&P Global Market Intelligence. The culprit for its dismal performance can be traced to its first-quarter earnings release on April 26.For the quarter, Pacific Biosciences reported a 60% year-over-year increase in revenue to $24.9 million. The increase was even more impressive on a product and service basis considering that last y...
Tags: California, Finance, Health Care, Sean Williams, Pacific Biosciences, 10% Promise, PACB, 68695880-2fa1-11e7-b54b-0050569d32b9, Pacific Biosciences Continue

Pacific Biosciences of California Reports Q1 Loss Due to Higher Costs

Pacific Biosciences of California (NASDAQ: PACB) experienced a double-whammy in the fourth quarter of 2016: The genetic-sequencing company had lower revenue and a bigger loss than the prior year period.It wasn't quite as bad when the company reported its 2017 first-quarter results Wednesday evening: This time, there was only a single whammy. Here are the highlights. Image source: Getty Images.Continue reading [Author: [email protected] (Keith Speights)]
Tags: California, Finance, Health Care, Pacific Biosciences, ILMN, Keith Speights, PACB, Bdbeb288-2b5c-11e7-92de-0050569d4be0

Here's Why Pacific Biosciences of California Is Sliding Today

Shares of Pacific Biosciences of California (NASDAQ: PACB)  are getting battered today in response to a wider-than-expected first-quarter loss, announced after the market closed yesterday. Shares of the genetic analysis technology company have fallen 22.5% as of 11:26 a.m. EDT during Thursday's session.Wall Street was expecting Pacific Biosciences to report a net loss in line with the first quarter of last year, or $0.23 per share. Instead, the company reported a loss of $0.26 per share, inciti...
Tags: California, Finance, Health Care, Pacific Biosciences, ILMN, 10% Promise, Cory Renauer, PACB, 08e470c2-2b58-11e7-8fab-0050569d4be0

Foresite Capital adds venture partner to team

Foresite Capital has hired Dr. Molly He as a venture partner. He is a former senior director at Illumina. PRESS RELEASE SAN FRANCISCO–(BUSINESS WIRE)–Foresite Capital, a healthcare growth equity firm, today announced that it has named Molly He, Ph.D., as venture partner. A former senior director at Illumina, Dr. He brings to Foresite more than 15 years of experience in pharmaceutical and genomic research and development. “Dr. He is one of the most respected scientific researchers in the area of ...
Tags: New York, San Francisco, Trends, People, Illumina, University of California Los Angeles, Nankai University, Pacific Biosciences, Foresite Capital, Molly He, Molly He Ph D, Foresite, Jim Tananbaum

Dingo Wins The World's Most Interesting Genome Competition

An anonymous reader shares a report: It sounds like an argument scientists might have during a night of drinking: Which creature has the most interesting genome in the world? But the question is more than a passing musing. San Francisco biotech company Pacific Biosciences held a public competition to determine which critter should receive the honor. The winner: Sandy Maliki, an Australian desert dingo. The company will now sequence the dingo's genome to help researchers study animal domesticatio...
Tags: San Francisco, Tech, Sandy, Pacific Biosciences, Sandy Maliki

The 'Explosive' Bombardier Beetle Got Robbed by a Dingo for the Title of Most Interesting Genome

This week, the Pacific Biosciences SMRT Grant announced the lucky winner of the World’s Most Interesting Genome competition. The contest was voted on by the public and a dingo named Sandy won the day. But was that the right decision? No, Sandy is kind of like a doggo and it’s clear that voters let her cuteness win out…Read more...
Tags: Science, Genome, Grant, Sandy, Pacific Biosciences, Wrong, Sea Slug, Pacific Biosciences SMRT Grant, Worlds Most Interesting Genome, Sandy The Dingo, Bombardier Beetle, Pitviper, The Pink Pigeon